TY - JOUR
T1 - Isolated limb perfusion
T2 - The European experience
AU - Lejeune, F. J.
AU - Kroon, B. B.R.
AU - Di Filippo, F.
AU - Hoekstra, H. J.
AU - Santinami, M.
AU - Liénard, D.
AU - Eggermont, A. M.M.
PY - 2001
Y1 - 2001
N2 - More than 40 years after its design in the United States isolated limb perfusion is still a very promising and progressing technique. In Europe, very interesting developments have been made. The optimalization of the method, especially by using continuous leakage monitoring and using the drug melphalan, yielded good results in melanoma and the addition of TNF is the first demonstration of an active antiangiogenic treatment in the clinic. Furthermore, in sarcomas that are not amenable to surgery, ILP with TNF and melphalan represents a neoadjuvant treatment for limb-sparing surgery. Being a regional treatment ILP is not expected to significantly influence survival. This treatment modality is worthwhile to pursue in the local control of regionally advanced tumors, avoiding unnecessary mutilation.
AB - More than 40 years after its design in the United States isolated limb perfusion is still a very promising and progressing technique. In Europe, very interesting developments have been made. The optimalization of the method, especially by using continuous leakage monitoring and using the drug melphalan, yielded good results in melanoma and the addition of TNF is the first demonstration of an active antiangiogenic treatment in the clinic. Furthermore, in sarcomas that are not amenable to surgery, ILP with TNF and melphalan represents a neoadjuvant treatment for limb-sparing surgery. Being a regional treatment ILP is not expected to significantly influence survival. This treatment modality is worthwhile to pursue in the local control of regionally advanced tumors, avoiding unnecessary mutilation.
UR - http://www.scopus.com/inward/record.url?scp=0035164903&partnerID=8YFLogxK
U2 - 10.1016/s1055-3207(18)30034-6
DO - 10.1016/s1055-3207(18)30034-6
M3 - Review article
C2 - 11641093
AN - SCOPUS:0035164903
SN - 1055-3207
VL - 10
SP - 821
EP - 832
JO - Surgical Oncology Clinics of North America
JF - Surgical Oncology Clinics of North America
IS - 4
ER -